Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Yarnoff

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Infectious Diseases and Therapy|February 26, 2026
Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling StudyBenjamin Yarnoff, Matthieu Beuvelet, Samira Soudani, et al.
Pulmonary Therapy|February 26, 2026
Estimation of Public Health Impact with Use of Nirsevimab During the 2024-2025 RSV Season in the USA: a Modeling StudyBenjamin Yarnoff, Maureen P Neary, Veronica Gabriel, et al.
BMC Geriatrics|May 28, 2026
Mortality and transitions-of-care after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysisAlon Yehoshua, Rachel M Black, Anan Zhou, et al.
Expert Review of Vaccines|November 18, 2025
Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohortAlexia Kieffer, Mehdi Ghemmouri, Samira Soudani, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Infectious Diseases and Therapy|February 26, 2026
Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling StudyBenjamin Yarnoff, Matthieu Beuvelet, Samira Soudani, et al.
Pulmonary Therapy|February 26, 2026
Estimation of Public Health Impact with Use of Nirsevimab During the 2024-2025 RSV Season in the USA: a Modeling StudyBenjamin Yarnoff, Maureen P Neary, Veronica Gabriel, et al.
BMC Geriatrics|May 28, 2026
Mortality and transitions-of-care after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysisAlon Yehoshua, Rachel M Black, Anan Zhou, et al.
Expert Review of Vaccines|November 18, 2025
Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohortAlexia Kieffer, Mehdi Ghemmouri, Samira Soudani, et al.
Pageof 4